ALMS (Alumis) EBITDA Margin %: -5,602.41% (As of Mar. 2026)


ALMS Alumis Inc ALMS
12 GF Score
Price $26.40
! 4 Warning Signs
View Full Analysis

What is Alumis EBITDA Margin %?

Alumis ALMS +5.52% 12 EBITDA Margin % is -5,602.41% as of Mar. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Alumis ranks worse than 90.57% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alumis's EBITDA for the three months ended in Mar. 2026 was $-97.54 Mil. Alumis's Revenue for the three months ended in Mar. 2026 was $1.74 Mil. Therefore, Alumis's EBITDA margin for the quarter that ended in Mar. 2026 was -5,602.41%.

Alumis  (NAS:ALMS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Alumis EBITDA Margin % Related Terms

Alumis EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Alumis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alumis EBITDA Margin % Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 -1,872.38

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -579.02 -5,238.90 -5,536.11 -4,954.80 -5,602.41

ALMS vs SLNO, ARQT, IRON: EBITDA Margin % Comparison

For the Biotechnology subindustry, Alumis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alumis EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alumis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alumis's EBITDA Margin % falls into.


ALMS
12GF Score
Alumis Inc ALMS
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alumis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alumis's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-450.308/24.05
=-1,872.38 %

Alumis's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-97.538/1.741
=-5,602.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -5,602.41% mean?
Alumis (ALMS) has a EBITDA Margin % of -5,602.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alumis and its competitors. According to the industry distribution chart, Alumis ranks #855 out of 944 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Alumis' EBITDA Margin % too high?
Alumis' current EBITDA Margin % is -5,602.41%. Based on the distribution chart, Alumis ranks #855 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' EBITDA Margin % compare to SLNO and ARQT?
According to the Biotechnology industry distribution chart, Alumis ranks #855 out of 944 companies for EBITDA Margin %. This places Alumis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alumis and its competitors. Alumis's current EBITDA Margin % is -5,602.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current EBITDA Margin % of -5,602.41%. The current EBITDA Margin % is -5,602.41%. Alumis' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alumis (ALMS), the current EBITDA Margin % is -5,602.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alumis Business Description

Address 280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score

Get the complete analysis for ALMS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.40
Price